NovoSeven (eptacog alfa) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 65 Diseases   5 Trials   5 Trials   404 News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NovoSeven (eptacog alfa) / Novo Nordisk
2019-003427-38: An international investigator trial to capture different approaches in the treatment of Hemophilia A Patients With FVIII Inhibitors

Ongoing
4
120
Europe, RoW
Octanate, Wilate, Nuwiq, Hemlibra, NovoSeven, Cevenfacta, Powder and solvent for solution for injection, Solution for injection, Octanate, Wilate, Nuwiq, Hemlibra, FEIBA NF 500 E/1000 E, NovoSeven, Cevenfacta
HZRM – Hämophilie-Zentrum Rhein Main GmbH, Octapharma AG
Inhibitor-Positive patients with Haemophilia A, Haemophilia A in patients who have developed inhibitors to any FVIII product., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT07157423: A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India

Recruiting
4
64
RoW
Eptacog alfa (NovoSeven)
Novo Nordisk A/S
Severe Postpartum Haemorrhage
08/27
08/27
MOTIVATE, 2024-516741-39-00`2019-003427-38: An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibitors

Recruiting
4
22
Europe
Nuwiq 2500 IU powder and solvent for solution for injection, NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection, OCTANATE 1000 Pulver und L?sungsmittel zur Herstellung einer Injektionsl?sung, FEIBA 1000 E Pulver und L?sungsmittel zur Herstellung einer Infusionsl?sung, Wilate 1000, 1000 I.E. VWF/1000 I.E. FVIII, Pulver und L?sungsmittel zur Herstellung einer intraven?sen Injektionsl?sung., Nuwiq 1500 IU powder and solvent for solution for injection, Hemlibra 150 mg/mL solution for injection, CEVENFACTA 1 mg (45 KIU) powder and solvent for solution for injection, NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection, Nuwiq 500 IU powder and solvent for solution for injection, CEVENFACTA 5 mg (225 KIU) powder and solvent for solution for injection, OCTANATE 500 Pulver und L?sungsmittel zur Herstellung einer Injektionsl?sung, Hemlibra 30 mg/mL solution for injection, NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection, Nuwiq 4000 IU powder and solvent for solution for injection, FEIBA 500 E Pulver und L?sungsmittel zur Herstellung einer Infusionsl?sung., OCTANATE 250 Pulver und L?sungsmittel zur Herstellung einer Injektionsl?sung, Nuwiq 3000 IU powder and solvent for solution for injection, CEVENFACTA 2 mg (90 KIU) powder and solvent for solution for injection, FEIBA 2500 E Pulver und L?sungsmittel zur Herstellung einer Infusionsl?sung., Nuwiq 1000 IU powder and solvent for solution for injection, Nuwiq 250 IU powder and solvent for solution for injection, Wilate 500, 500 I.E. VWF/500 I.E. FVIII, Pulver und L?sungsmittel zur Herstellung einer intraven?sen Injektionsl?sung., Nuwiq 2000 IU powder and solvent for solution for injection, NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection
HZRM Haemophilie-Zentrum Rhein Main GmbH, Emory University, Octapharma AG, Switzerland
Haemophilia A
 
 
2019-003722-25: Recombinant Factor VIIa for acute bleeding in the brain (Hemorrhagic Stroke) administered at earliest Time - (FASTEST) Trial

Not yet recruiting
3
860
Europe, RoW
NovoSeven 5mg (250 KIU), Powder and solvent for solution for injection, NovoSeven 5mg (250 KIU)
University of Cincinnati, National Institute of Neurological Disorders and Stroke (NINDS), NovoNordisk A/S, National Institute of Neurological Disorders and Stroke, NINDS, Novo Nordisk A/S
Acute Hemorrhagic Stroke, Acute bleeding into the brain, Diseases [C] - Nervous System Diseases [C10]
 
 
2019-002854-22: CLINICAL TRIAL COMPARING PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY OFA BIOSIMILAR EPTACOG ALFA (ARYOSEVEN) AND NOVOSEVEN®, INPATIENTS WITH HAEMOPHILIA A OR B WITH INHIBITORS

Not yet recruiting
3
48
Europe
AryoSeven, NovoSeven, Powder and solvent for solution for injection, NovoSeven
Aryogen Pharmed, Aryogen Pharmed
HAEMOPHILIA A OR B WITH INHIBITORS, HAEMOPHILIA A OR B WITH INHIBITORS, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
FASTEST Part 2, NCT07227246: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Recruiting
3
350
Europe, Canada, Japan, US
Recombinant Factor VIIa, NovoSeven NiaStase, Biological/Vaccine: Placebo
Joseph Broderick, MD, National Institute of Neurological Disorders and Stroke (NINDS), Japan Agency for Medical Research and Development, Novo Nordisk A/S
Intracerebral Hemorrhage
01/29
06/29
WILL-EMI, NCT06998524 / 2024-515622-80-00: A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Recruiting
3
75
Europe, Canada, Japan, US, RoW
Emicizumab, Hemlibra, RO5534262, RG6013, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
Hoffmann-La Roche, F. Hoffmann-La Roche AG
Von Willebrand Disease, Type 3
04/27
04/29
FASTEST, NCT03496883 / 2024-517383-28-00 / 2019-003722-25: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Active, not recruiting
3
860
Europe, Canada, Japan, US
Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo
Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS)
Acute haemorrhagic stroke
01/28
01/28
WP45338, 2024-515622-80-00: A Study to assess safety and effectiveness of Emicizumab in Patients with Type 3 Von Willebrand Disease

Recruiting
2/3
47
Europe
NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection, ADVATE 1 500 IU/2 ml powder and solvent for solution for injection, Haemate? P 600 IE vWF / 250 IE FVIII Pulver und L?sungsmittel zur Herstellung einer Injektions- oder Infusionsl?sung., ELOCTA 1500 IU Powder and solvent for solution for injection, Haemate? P 1200 IE vWF / 500 IE FVIII Pulver und L?sungsmittel zur Herstellung einer Injektions- oder Infusionsl?sung, Wilate 1000, 1000 IU VWF/1000 IUFVIII, powder and solvent for solution for injection, ELOCTA 1000 IU Powder and solvent for solution for injection, VEYVONDI 1300 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection., ELOCTA 250 IU Powder and solvent for solution for injection, Wilate 500, 500 IU VWF/500 IUFVIII, powder and solvent for solution for injection, NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection, ELOCTA 750 IU Powder and solvent for solution for injection, ELOCTA 3000 IU Powder and solvent for solution for injection, Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, FEIBA 50 U/ml powder and solvent for solution for infusion, Voncento 1000 IU FVIII / 2400 IU VWF (10 ml solvent) powder and solvent for solution for injection/infusion, Haemate? P 2400 IE vWF / 1000 IE FVIII Pulver und L?sungsmittel zur Herstellung einer Injektions- oder Infusionsl?sung, ELOCTA 2000 IU Powder and solvent for solution for injection, Hemlibra 150 mg/mL solution for injection, NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection, Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, Voncento 500 IU FVIII /1200 IU VWF (10 ml solvent) powder and solvent for solution for injection/infusion, Willfact 2000 IU Powder and solvent for solution for injection, NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection, ELOCTA 4000 IU powder and solvent for solution for injection, Fanhdi 500 IU powder and solvent for solution for injection., ELOCTA 500 IU Powder and solvent for solution for injection
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG
Type 3 Von Willebrand Disease
 
 
U1111-1201-0087, 2024-517383-28-00`2019-003722-25: Recombinant coagulation Factor VIIa administered at the earliest time for the treatment of stroke caused by bleeding in the brain - FASTEST Trial

Recruiting
2/3
125
Europe
NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection, Eptacog alfa Placebo
University Of Cincinnati College Of Medicine, NovoNordisk A/S, Denmark, National Institute of Neurological Disorders and Stroke (NINDS), USA
Acute haemorrhagic stroke
 
 
2013-005036-20: Recombinant Factor VIIa: Local treament of severe bleedings after delivery

Completed
2
10
Europe
Recombinant Activated Factor VII, Powder and solution for solution for injection, NovoSevenRT
Stellaris Pharmaceuticals ApS, Stellaris Pharmaceuticals ApS
Severe postpartum bleeding Desuden indgår 5 personer, der får foretaget sektio af anden årsag, som kontrol med hensyn til måling af koagulationsparametre inden og 15 minutter efter fjernelse af placrenta., Severe Bleeding after delivery, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
NCT06010953: SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Completed
1/2
24
RoW
SS109
Jiangsu Gensciences lnc.
Male, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Hemophilia
05/24
05/24
NCT04768699 / CTR20202311: Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

Recruiting
1
24
RoW
TQG203, TQG203/NovoSeven®
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
12/21
12/21
MOTIVATE, NCT04023019 / 2024-516741-39-00 / 2019-003427-38: Treatment of Hemophilia A Patients With FVIII Inhibitors

Recruiting
N/A
120
Europe, US
Nuwiq, Octanate, Wilate, Emicizumab, Hemlibra, Recombinant factor VIIa (rFVIIa), NovoSeven, Activated prothrombin complex concentrate (aPCC), FEIBA
Emory University, Octapharma
Haemophilia A
12/28
06/29

Download Options